Raben Dorthe, Jakobsen Marie L, Trajanovska Jamina, Kowalska Justyna, Vassilenko Anna, Dragas Snezana, Harxhi Arjan, Dragovic Gordana, Jaschinski Nadine J, Neesgaard Bastian, Hjorth-Larsen Klaus, Garges Harmony, Gallant Joel, Lundgren Jens D, Philips Andrew, Cambiano Valentina, Yazdanpanah Yazdan, Mocroft Amanda
CHIP, Rigshospitalet, University of Copenhagen, Denmark.
University Clinic for Infectious Diseases & Febrile Conditions, Skopje, North Macedonia.
PLoS One. 2025 Jan 29;20(1):e0316794. doi: 10.1371/journal.pone.0316794. eCollection 2025.
Many HIV clinics with poor IT-infrastructure are unable to report data on individuals in care with HIV, on antiretroviral treatment (ART) and virologically suppressed (VS), with the aim of monitoring the HIV Continuum of Care to estimate efficacy of HIV treatment programmes. We developed an estimation-tool, ESTIHIV, and determined the minimal data required for a random sample, to produce representative estimates, with a specified level of precision, of people with HIV on ART and VS. For proof of concept, 8852 HIV positive persons from seven clinics in seven different countries, with a follow-up visit during 2017, were included. Of those, 93.8% were on ART (95% CI 93.3-94.2) and 76.7% were VS (95% CI 75.8-77.6). In 2022, we tested the tool in the RESPOND Cohort for all countries with more than 100 participants under follow-up in 2019. We included 26,426 HIV positive persons from clinics in 27 countries, 97.8% (95% CI 97.6-98.0) were on ART and 91.5% were VS (95% CI 91.2-91.8%). There was good agreement between the RESPOND country estimates of ART and VS and the estimations using a random sample calculated in ESTIHIV. With ESTIHIV, clinics can produce a reliable estimate in figures for reporting and for monitoring the effectiveness of care in their clinics.
许多信息技术基础设施较差的艾滋病诊所无法报告接受艾滋病治疗、抗逆转录病毒治疗（ART）和病毒学抑制（VS）的患者数据，目的是监测艾滋病连续护理情况，以评估艾滋病治疗项目的效果。我们开发了一种估算工具ESTIHIV，并确定了随机样本所需的最少数据，以便在指定的精度水平下，对接受抗逆转录病毒治疗且病毒学抑制的艾滋病患者进行具有代表性的估算。为了进行概念验证，纳入了来自七个不同国家七个诊所的8852名艾滋病毒阳性患者，这些患者在2017年期间接受了随访。其中，93.8%的患者接受了抗逆转录病毒治疗（95%置信区间93.3 - 94.2），76.7%的患者病毒学抑制（95%置信区间75.8 - 77.6）。2022年，我们在RESPOND队列中对2019年随访参与者超过100人的所有国家测试了该工具。我们纳入了来自27个国家诊所的26426名艾滋病毒阳性患者，97.8%（95%置信区间97.6 - 98.0）的患者接受了抗逆转录病毒治疗，91.5%的患者病毒学抑制（95%置信区间91.2 - 91.8%）。RESPOND国家对接受抗逆转录病毒治疗和病毒学抑制情况的估计与使用ESTIHIV计算的随机样本估计之间存在良好的一致性。使用ESTIHIV，诊所可以得出可靠的数字估计，用于报告和监测其诊所护理的有效性。
